• Ligang Chen, Jing Ma, Zheng Zou, Hongzhe Liu, Chenxin Liu, Shun Gong, Xu Gao, and Guobiao Liang.
• Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, China.
• Medicine (Baltimore). 2022 Nov 25; 101 (47): e32042e32042.

BackgroundTo fully understand the clinical features and prognosis of Glioblastoma (GBM), we extracted the data from the Surveillance, Epidemiology, and End Results (SEER) database and performed a series of analyses.MethodsWe retrospectively analyzed the data of 1674 patients with GBM obtained from the SEER database from 1983 to 2015. Kaplan-Meier analysis was performed to calculate the survival rate, and the log-rank test was used to analyze the survival outcomes.ResultsOlder patients with GBM had a worse survival period (P < .05). Laterality had no effect on the prognosis (P > .05). Patients with high-grade gliomas may have a shorter lifespan (P < .05). In terms of overall survival (OS) and disease specificity, all 3 classical treatments failed to improve the life expectancy (P > .05). In adult patients with GBM, we found that age, tumor grade, surgery, radiotherapy, and chemotherapy were independent risk factors for all-cause mortality. In the univariate disease-specific analysis, age, tumor grade, surgery, radiotherapy, and chemotherapy were independent risk factors. However, in multivariate disease-specific analysis, the results showed that only tumor grade and surgery were independent risk factors for GBM.ConclusionsOlder patients diagnosed with GBM have worse survival, and patients with glioma of higher grades have a shorter lifespan. Age, grade, surgery, radiation therapy, and chemotherapy were independent prognostic factors for patients with GBM.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

8 keywords...

hide…